RxDoctor Payments Data

Manmeet Brar, MD

Nephrology · Dover, DENPI 1043285471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $657 and has fallen 92.1% since, to $52 in 2025. That places this record below the midpoint for nephrology clinicians in DE, where the typical reported total is $2,465.

$2,234in general payments, 2019–2025

Across 104 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$464
  • Amgen$204
  • Fresenius USA Marketing, Inc.$195
  • Vifor Pharma, Inc.$195
  • Akebia Therapeutics Inc$169
  • Otsuka America Pharmaceutical, Inc.$121
  • plus $885 from 17 others

What the payments were for

  • Food & beverage$2,11595%
  • Education$1185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,234 in reported general payments places this provider in the 45th percentile of 49 nephrology providers in Delaware.

See all nephrology providers in Delaware

Medicare billing

Part B allowed, 2024
$95,897
Medicare patients
350
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa13$14,146
Potassium Citrate ErPotassium Citrate16$2,299
Nifedipine ErNifedipine11$1,385
Metoprolol Succinate33$1,139
Calcitriol32$765
Losartan Potassium33$537
Amlodipine Besylate41$400
Hydralazine Hcl18$282
Allopurinol12$187
Furosemide21$78

Paid to pharmacies, not to this prescriber.

Other nephrology in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →